Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of KER-050 With or Without Ruxolitinib in Myelofibrosis
2021-003227-15Phase 2Active
- Sponsor
- Keros Therapeutics
- Start
- Sep 2021
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of elritercept in myelofibrosis (MF) (2 arms), sponsored by Keros Therapeutics. Primary endpoints: Safety and tolerability and Pharmacokinetics of KER-050. Started Sep 2021; status: active.
02
Drugs
elritercept
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on 2021-003227-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003227-15.